Kanamycin-Pos (Kanamycin Monosulphate)

Kanamycin interferes with bacterial protein synthesis by binding to the 30S ribosomal subunit. This binding causes misreading of messenger RNA and premature termination of peptide chains, leading to rapid bacterial cell death. The mechanism is effective against many Gram‑negative and some Gram‑positive ocular pathogens.

The dosing regimen for Kanamycin-Pos is determined by the prescribing clinician based on the severity of the infection, the specific ocular condition, patient age and renal function. The product is supplied as a ready‑to‑use ophthalmic preparation, and the prescriber specifies the number of drops and frequency.

Safety data for topical kanamycin during pregnancy and lactation are limited. Use is generally avoided unless the potential benefit to the mother outweighs any possible risk to the fetus or infant. Clinicians should discuss risks with the patient and consider alternative therapies when appropriate.

To order Kanamycin-Pos, submit an enquiry on the product page at gnhindia.com, indicating the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets. The sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including any cold‑chain requirements) and import documentation.

Kanamycin‑Pos belongs to the aminoglycoside class, offering strong activity against many Gram‑negative organisms and some Gram‑positive strains. Compared with fluoroquinolone eye drops, kanamycin may be preferred for infections resistant to fluoroquinolones, but it carries a higher risk of local irritation and rare systemic toxicity. Choice depends on microbial susceptibility and patient tolerance.

Kanamycin‑Pos should be stored at temperatures below 25 °C, in its original container, protected from moisture and direct light. Do not freeze the product. Once opened, use within the period specified on the label and discard any solution that appears discoloured or contaminated.

The ophthalmic solution is applied as directed by the prescriber, typically by instilling one to two drops into the affected eye(s) at the prescribed interval. Patients should wash their hands before use, avoid touching the dropper tip to the eye or any surface, and gently close the eye for a few seconds after instillation to enhance absorption.

Serious adverse events, although rare, include corneal ulceration, severe allergic reactions such as swelling, rash or anaphylaxis, and systemic ototoxicity leading to hearing loss if significant absorption occurs. Any sudden worsening of ocular symptoms or systemic signs should prompt immediate medical evaluation and discontinuation of the product.

Kanamycin‑Pos is contraindicated in patients with a known hypersensitivity to kanamycin, other aminoglycosides, or any component of the formulation. Caution is advised in neonates, infants, and patients with impaired renal function, as systemic absorption may be higher. It should also be avoided in individuals receiving concurrent systemic aminoglycoside therapy unless closely monitored.